Funded Biotechnology Startups in San Francisco
The 50 most recent funding rounds for San Francisco biotechnology companies span from October 2023 through November 2025, covering a wide range from $80,00…
The 50 most recent funding rounds for San Francisco biotechnology companies span from October 2023 through November 2025, covering a wide range from $80,000 venture tranches at Revel Pharmaceuticals to Olema Oncology's $250M raise in December 2024. The largest disclosed rounds include Tenvie Therapeutics ($200M Series A, January 2025), Bluejay Therapeutics ($182M Series C, May 2024), and Nurix Therapeutics ($175M, April 2024). Nudge closed a $100M Series A in July 2025, and Until Labs followed with a $58M Series A in September 2025.
Seed activity remains consistent throughout the window, with Hermes Biosciences ($6M, November 2025), General Proximity ($16M, January 2025), and Alessa Therapeutics ($15M, December 2024) among recent entrants. Oncology-named companies — Olema Oncology, UP Oncolytics, and ALX Oncology — recur across multiple cohorts. A notable share of rounds carry the "Series Unknown" designation or undisclosed amounts, reflecting the prevalence of crossover financings and strategically structured deals that don't map cleanly to standard stage classifications.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Olema Oncology raised $250M in December 2024, Tenvie Therapeutics closed a $200M Series A in January 2025, Bluejay Therapeutics raised $182M at Series C in May 2024, and Nurix Therapeutics raised $175M in April 2024. Aligos Therapeutics ($105M, February 2025) and Nudge ($100M Series A, July 2025) are the next largest disclosed raises among the 50 companies shown.
How active is seed-stage funding among San Francisco biotech companies in this list?
Nine of the 50 companies raised seed rounds, the most recent being Hermes Biosciences ($6M, November 2025). Other recent seeds include General Proximity ($16M, January 2025), Alessa Therapeutics ($15M, December 2024), and Granza Bio ($7M, July 2024), with sizes ranging from $2M at Alixia to $16M at General Proximity.
Which biotech sub-areas are most visible based on company names in this funding data?
Three companies carry explicit oncology designations — Olema Oncology, UP Oncolytics, and ALX Oncology — spanning multiple round types and dates. Longevity and aging biology is also represented, with OneSkin ($20M Series A, August 2025) and Junevity ($10M seed, February 2025) among the more recently active companies in that category.
How common are undisclosed amounts and unclassified round types in this segment?
At least eight companies — including Mana.bio, Mission Bio, LTZ Therapeutics, and Siren Biotechnology — did not disclose round sizes. A substantial share of rounds carry the 'Series Unknown' label, reflecting the frequency of crossover, strategic, and non-publicly-structured financings in this market.
Are late-stage companies still raising active rounds in San Francisco biotech?
Circle Pharma closed a $90M Series D in September 2024, and Bluejay Therapeutics ($182M Series C), Asher Bio ($55M Series C), and Frontier Medicines ($20M Series C) all raised Series C rounds across 2024. Multiple Series B companies — Prolific Machines ($55M), Attralus ($56M), and GALY ($33M) — also appear in the dataset, indicating sustained capital activity at growth stages.
What does the most recent funding activity in this list look like?
The most recent close is Hermes Biosciences' $6M seed round on November 23, 2025, followed by Revel Pharmaceuticals' $80,000 venture round on October 9, 2025. Until Labs raised a $58M Series A on September 23, 2025, and Mana.bio closed an undisclosed seed round on September 14, 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.